In an EGFR mutation-positive NSCLC clinical trial, nivolumab in combination with Erlotinib (EGFR TKI) resulted in tolerable safety profile with an ORR of 19%, and durable response was observed in four out of 20 patients (48). This evidence concerns the gene EGFR and non-small cell lung carcinoma.